Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$0.65
-3.8%
$0.37
$0.22
$2.54
$42.15M0.884.21 million shs3.13 million shs
DURECT Corporation stock logo
DRRX
DURECT
$0.54
+2.1%
$0.60
$0.48
$1.74
$16.27M0.6450,032 shs40,385 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$0.55
+14.8%
$0.33
$0.24
$1.47
$34.08M0.13558,318 shs3.44 million shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.59
+0.3%
$3.21
$1.75
$8.62
$5.88M1.33798,959 shs43,347 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-3.82%+15.26%+133.57%+75.62%-65.94%
DURECT Corporation stock logo
DRRX
DURECT
+2.14%-14.45%-18.49%-28.22%-62.83%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
+14.75%+35.80%+85.87%+90.58%-46.08%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+0.28%-0.55%+25.96%+56.09%+741.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3.1172 of 5 stars
3.53.00.00.03.71.70.6
DURECT Corporation stock logo
DRRX
DURECT
0.4991 of 5 stars
0.03.00.04.40.00.00.0
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
4.6065 of 5 stars
3.65.00.04.61.82.50.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.8153 of 5 stars
0.05.00.00.02.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3.00
Buy$2.83333.23% Upside
DURECT Corporation stock logo
DRRX
DURECT
2.00
HoldN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3.20
Buy$3.13468.18% Upside
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SNOA, CGTX, OVID, and DRRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
5/27/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $3.00
5/27/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.00 ➝ $1.50
5/8/2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $4.00
4/24/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/A$0.31 per shareN/A
DURECT Corporation stock logo
DRRX
DURECT
$2.03M8.19N/AN/A$0.29 per share1.85
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$548K71.37N/AN/A$0.96 per share0.57
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.41N/AN/A$2.73 per share1.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$33.97M-$0.74N/AN/AN/AN/A-194.42%-115.14%8/6/2025 (Estimated)
DURECT Corporation stock logo
DRRX
DURECT
-$8.32M-$0.15N/AN/AN/A-91.54%-267.36%-64.00%8/12/2025 (Estimated)
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.10N/AN/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)

Latest SNOA, CGTX, OVID, and DRRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.11N/AN/AN/AN/AN/A
8/12/2025Q2 2025
DURECT Corporation stock logo
DRRX
DURECT
-$0.13N/AN/AN/A$0.32 millionN/A
8/12/2025Q2 2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.16N/AN/AN/A$0.09 millionN/A
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
5/13/2025Q1 2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million
5/6/2025Q1 2025
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.12-$0.14-$0.02-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/AN/A
DURECT Corporation stock logo
DRRX
DURECT
N/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/A
2.09
2.09
DURECT Corporation stock logo
DRRX
DURECT
N/A
1.23
1.22
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.22
4.93
4.93
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38

Institutional Ownership

CompanyInstitutional Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
43.35%
DURECT Corporation stock logo
DRRX
DURECT
28.03%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
72.24%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
14.40%
DURECT Corporation stock logo
DRRX
DURECT
3.20%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
13.10%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2061.99 million53.07 millionNot Optionable
DURECT Corporation stock logo
DRRX
DURECT
8031.04 million30.05 millionOptionable
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
6071.11 million61.80 millionOptionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.58 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cognition Therapeutics stock logo

Cognition Therapeutics NASDAQ:CGTX

$0.65 -0.03 (-3.82%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.66 +0.01 (+1.38%)
As of 07/18/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

DURECT stock logo

DURECT NASDAQ:DRRX

$0.54 +0.01 (+2.14%)
As of 07/18/2025 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$0.55 +0.07 (+14.75%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.56 +0.01 (+1.09%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.59 +0.01 (+0.28%)
Closing price 07/18/2025 03:46 PM Eastern
Extended Trading
$3.54 -0.05 (-1.53%)
As of 07/18/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.